Compare Enveric Biosciences Inc (ENVB) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Tyson Foods, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.39 (market cap $5.32M), while Tyson Foods, Inc. trades at $57.92 (market cap $20.24B). The key difference: Tyson Foods, Inc. is far larger — about 3804.5× Enveric Biosciences Inc's market cap, and Tyson Foods, Inc. pays a 3.55% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | TSN | |
|---|---|---|
Market Cap | $5.32M | $20.24B |
Sector | Health | Consumer Staples |
52-Week High | $17.40 | $68.75 |
52-Week Low | $1.28 | $50.72 |
Enterprise Value | $408.82K | $27.82B |
Dividend Yield | — | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Tyson Foods (TSN) trades at $57.48, down 0.76% on the day, with a bearish technical signal but strong analyst support. The stock shows mixed fundamentals with a low P/S ratio of 0.37 and P/B of 1.12, but elevated P/E of 45.25 reflects thin net margins of 0.81%. Recent earnings have been inconsistent, beating estimates in Q3 2025 and Q1 2026 but missing in Q4 2025. The company maintains steady dividends and is focusing on growth in prepared foods.
The outlook presents a value opportunity with a consensus price target of $68.80 offering ~20% upside, supported by 50% analyst buy ratings. However, risks include volatile earnings, compressed profit margins, and significant debt load. The bearish technical picture suggests near-term pressure, while strategic initiatives in value-added products could drive long-term recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
